The persistent viral infections in the development and severity of myalgic encephalomyelitis/chronic fatigue syndrome.
Rasa-Dzelzkaleja, Santa, Krumina, Angelika, Capenko, Svetlana et al. · Journal of translational medicine · 2023 · DOI
Quick Summary
This study examined whether three common viruses—HHV-6, HHV-7, and parvovirus B19—play a role in ME/CFS by comparing 200 ME/CFS patients with 150 healthy people. The researchers found that ME/CFS patients were much more likely to have these viruses in an active state (replicating) rather than dormant, and those with active infections had higher levels of inflammatory markers. The severity of ME/CFS symptoms appeared linked to the presence and activity level of these viral infections.
Why It Matters
Understanding the role of persistent viral infections in ME/CFS could explain the immune dysfunction observed in many patients and may eventually guide treatment strategies targeting viral reactivation. This research provides biological evidence supporting the hypothesis that ME/CFS has an infectious component, validating patient experiences of post-viral illness onset.
Observed Findings
Active viral infection (HHV-6A/B, HHV-7, and/or B19V) was detected in 45% of ME/CFS patients compared to only 8.7% of healthy controls.
Patients with active infections had 2-3 times higher viral loads than those with latent infections (e.g., HHV-6A/B: 653.2 vs 262 copies/10⁶ cells).
ME/CFS patients with active infections showed significantly elevated levels of pro-inflammatory cytokines IL-6, TNF-α, and IL-12, as well as anti-inflammatory IL-10.
Viral load and inflammatory marker levels were significantly higher in patients with severe ME/CFS compared to those with moderate disease.
Multiple concurrent infections (co-infections) were associated with higher cytokine levels than single infections.
Inferred Conclusions
Persistent viral infections in an active replicative state are significantly more common in ME/CFS patients than healthy individuals and may contribute to disease development.
Viral reactivation may drive the inflammatory response characteristic of ME/CFS, with higher viral loads correlating with greater symptom severity.
These three viruses may act synergistically in ME/CFS pathogenesis, as co-infections showed greater inflammatory effects than single infections.
Remaining Questions
Does viral reactivation cause ME/CFS, or does ME/CFS impair immune control of latent viruses? A longitudinal study following initially uninfected individuals would clarify temporal relationships.
What This Study Does Not Prove
This study does not prove these viruses cause ME/CFS—finding an association is not the same as proving causation. The presence of active infections in some healthy individuals suggests these viruses alone are insufficient to develop ME/CFS, meaning other factors (genetic, immunological, or environmental) likely contribute. Additionally, cross-sectional design prevents determining whether viral reactivation triggers ME/CFS or whether ME/CFS itself causes viral reactivation.
What specific immune defects allow these viruses to reactivate in ME/CFS patients but not in healthy seropositive individuals?
Are antiviral treatments targeting these reactivated infections effective in reducing ME/CFS symptom severity, and which patient subgroups would benefit most?
What role do genetic factors and other co-infections (EBV, CMV) play alongside HHV-6, HHV-7, and B19V in ME/CFS pathogenesis?